Announcement on Convening the 2025 Semi-annual Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening the 2025 Semi-annual Performance Briefing
Filed with SSE · · 2 pages · Chinese
Release
Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. on 6ix
Earlier from Beijing Wantai Biological Pharmacy Enterprise
- Announcement on Expected Decrease in Semi-annual Performance for 2025
- Announcement on Initiating Phase III Clinical Trial of Freeze-dried Live Attenuated Varicella-Zoster Vaccine (VZV-7D) and Completing Enrollment of the 1st Subject
- Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management
- Announcement on Approval of the Application for Marketing Authorization of 9-valent HPV Vaccine
- Announcement on Result of Share Reduction by Shareholder through Call Auction
Later from Beijing Wantai Biological Pharmacy Enterprise
- Announcement on the First Batch Release Certificate Obtained for 9-Valent Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
- Announcement on Resolutions of the 10th Meeting of the 6th Board of Directors
- Announcement on Resolutions of the 11th Meeting of the 6th Board of Directors
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Announcement on Resolutions of the 12th Meeting of the 6th Board of Supervisors
Follow Beijing Wantai Biological Pharmacy Enterprise into a list and get an email when it puts out news.
Follow Beijing Wantai Biological Pharmacy Enterprise